Asbury R, Blessing J A, Buller R, Malfetano J H, Walker J, Sevin B U
University of Rochester School of Medicine, New York, USA.
Am J Clin Oncol. 1998 Apr;21(2):145-6. doi: 10.1097/00000421-199804000-00010.
Twenty-six evaluable patients who had leiomyosarcoma of the uterus were treated with amonafide, 300 mg/m2, for 5 consecutive days every 3 weeks. One partial response (4%) resulted. Hematologic toxicity was substantial, with grade 3 or 4 events occurring as follows: leukopenia, 12 patients (46%); thrombocytopenia, 4 patients (15%); and granulocytopenia, 7 patients (27%). One patient had transient grade 4 renal failure. Considering the poor activity and substantial toxicity that was observed, no further studies are planned by the Gynecologic Oncology Group using amonafide at this dose schedule in leiomyosarcomas.
